期刊
JOURNAL OF ENDOCRINOLOGY
卷 221, 期 3, 页码 363-369出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/JOE-14-0084
关键词
diabetes; glucose metabolism; liver; metabolism
资金
- National Institute of Diabetes and Digestive and Kidney Diseases [R00DK085142, R01 DK63349]
- JHU-UMD Diabetes Research Center [P60DK079637]
- Johns Hopkins Institute for Clinical and Translational Research
- National Center for Advancing Translational Sciences [UL1TR000424-06]
Metformin is a first-line, anti-diabetic agent prescribed to over 150 million people worldwide. The main effect of metformin is to suppress glucose production in the liver; however, there is no reliable biomarker to assess the effectiveness of metformin administration. Our previous studies have shown that phosphorylation of CBP at S436 is important for the regulation of hepatic glucose production by metformin. In current study, we found that CBP could be phosphorylated in white blood cells (WBCs), and CBP phosphorylation in the liver and in WBCs of mice had a similar pattern of change during a fasting time course experiment. These data suggests that CBP phosphorylation in WBCs may be used as a biomarker of metformin action in the liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据